NCT07922174
A Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Area Under the Concentration-Time Curve from Time 0 to 12 Hours (AUC0-12) of MK-6916 on Day 16
Timeframe: Day 16: Predose and at designated timepoints (up to approximately 12 hours postdose)
Secondary (39)
AUC0-12 of MK-6916 on Day 1
Maximum Plasma Concentration (Cmax) of MK-6916 on Day 1
Cmax of MK-6916 on Day 16
Plasma Concentration at 12 Hours (C12) of MK-6916 on Day 1
C12 of MK-6916 on Day 16
Show 34 moreShow less
Time to Maximum Plasma Concentration (Tmax) of MK-6916 on Day 1
Tmax of MK-6916 on Day 16
Apparent Terminal Half-life (t1/2) of MK-6916 on Day 16
Clearance at Steady State (CL,ss/F) of MK-6916 on Day 16
Apparent Volume of Distribution at Steady State (Vz,ss/F) of MK-6916 on Day 16
AUC0-12 of MK-6916 Metabolite M5 on Day 1
AUC0-12 of MK-6916 Metabolite M9 on Day 1
AUC0-12 of MK-6916 Metabolite M10 on Day 1
AUC0-12 of MK-6916 Metabolite M5 on Day 16
AUC0-12 of MK-6916 Metabolite M9 on Day 16
AUC0-12 of MK-6916 Metabolite M10 on Day 16
Cmax of MK-6916 Metabolite M5 on Day 1
Cmax of MK-6916 Metabolite M5 on Day 16
Cmax of MK-6916 Metabolite M9 on Day 1
Cmax of MK-6916 Metabolite M9 on Day 16
Cmax of MK-6916 Metabolite M10 on Day 1
Cmax of MK-6916 Metabolite M10 on Day 16
C12 of MK-6916 Metabolite M5 on Day 1
C12 of MK-6916 Metabolite M5 on Day 16
C12 of MK-6916 Metabolite M9 on Day 1
C12 of MK-6916 Metabolite M9 on Day 16
C12 of MK-6916 Metabolite M10 on Day 1
C12 of MK-6916 Metabolite M10 on Day 16
Tmax of MK-6916 Metabolite M5 on Day 1
Tmax of MK-6916 Metabolite M5 on Day 16
Tmax of MK-6916 Metabolite M9 on Day 1
Tmax of MK-6916 Metabolite M9 on Day 16
Tmax of MK-6916 Metabolite M10 on Day 1
Tmax of MK-6916 Metabolite M10 on Day 16
t1/2 of MK-6916 Metabolite M5 on Day 16
t1/2 of MK-6916 Metabolite M9 on Day 16
t1/2 of MK-6916 Metabolite M10 on Day 16
Number of Participants Who Experience an Adverse Event (AE)
Number of Participants Who Discontinue Study Treatment Due to an AE
Arms and interventions
Panel A: Severe Renal ImpairmentExperimental
Participants with severe renal impairment will receive multiple doses of MK-6916 on Days 1-15 and a single oral dose on Day 16 under fasting conditions.
Panel B: Moderate Renal ImpairmentExperimental
Participants with moderate renal impairment will receive multiple doses of MK-6916 on Days 1-15 and a single oral dose on Day 16 under fasting conditions.
Panel C: HealthyExperimental
Healthy participants will receive multiple doses of MK-6916 on Days 1-15 and a single oral dose on Day 16 under fasting conditions.
Drugs: MK-6916